Egetis Therapeutics AB (publ) announced that Peder Walberg will assume the role of interim Chief Medical Officer. He replaces Stefan Carlsson who has decided to leave the company to pursue other opportunities. Peder Walberg takes on the position as interim CMO in addition to his current part time role within the company with focus on business development and the continued clinical development of the company’s lead candidate drug, Emcitate®. Peder will also continue as a member of the Board of Directors.